Viyash Scientific Releases Q3FY26 Investor Presentation with Business Updates
Viyash Scientific Limited submitted its comprehensive Q3FY26 investor presentation to BSE and NSE, providing detailed business updates following the merger completion. The presentation highlighted strong financial performance with revenue growth of 10.9% and significant EBITDA margin expansion, while showcasing progress in merger synergy realization across R&D, manufacturing, and business operations.
*this image is generated using AI for illustrative purposes only.
Viyash Scientific Limited has released its comprehensive investor presentation for Q3FY26 to the stock exchanges, providing detailed insights into the company's performance following the completion of its merger. The presentation was submitted to BSE Limited and National Stock Exchange of India Limited on February 06, 2026, under Regulation 30 of SEBI Listing Regulations.
Q3FY26 Performance Highlights
The investor presentation reaffirmed the company's strong Q3FY26 performance, with consolidated revenue reaching ₹8,584 million, representing 10.9% year-on-year growth. The presentation highlighted significant EBITDA improvement of 64.4% to ₹1,854 million with margin expansion to 21.6% from 14.6% in the previous year.
| Performance Metric: | Q3FY26 | Q3FY25 | Growth (%) |
|---|---|---|---|
| Revenue: | ₹8,584 million | ₹7,740 million | +10.9% |
| EBITDA: | ₹1,854 million | ₹1,127 million | +64.4% |
| EBITDA Margin: | 21.6% | 14.6% | +700 bps |
| Net Debt to LTM EBITDA: | 0.4x | 1.2x | Improvement |
Business Segment Performance
The presentation detailed broad-based revenue growth across all business segments. Formulations business reported ₹4,809 million in Q3FY26 compared to ₹4,009 million in Q3FY25, marking 20% growth. APIs segment generated ₹3,658 million versus ₹3,556 million in the previous year, representing 3% growth.
| Business Segment: | Q3FY26 | Q3FY25 | Growth (%) |
|---|---|---|---|
| Formulations: | ₹4,809 million | ₹4,009 million | +20% |
| APIs: | ₹3,658 million | ₹3,556 million | +3% |
| Europe Formulations: | ₹1,790 million | ₹1,334 million | +34% |
| Emerging Markets: | ₹1,630 million | ₹1,366 million | +19% |
Merger Integration Progress
The presentation provided comprehensive updates on merger synergy realization across key areas. In R&D, the company has achieved full API R&D integration leading to accelerated development, with 4 new animal health products developed and validated. Manufacturing synergies include validation of 6 intermediates at Viyash sites that were previously procured externally.
| Integration Area: | Key Achievements |
|---|---|
| R&D Integration: | 4 new animal health products developed |
| Manufacturing: | 6 intermediates validated internally |
| Cost Improvement: | 3 projects completed |
| EU Approval: | New production block commercialized |
Market Opportunity and Strategic Vision
The investor presentation outlined significant market opportunities in the animal health sector, particularly in companion animals where generic penetration remains below 15% compared to 91% in human health. The company highlighted the growing companion animal market expected to reach $32-35 billion by 2030 from $16 billion in 2020.
Manufacturing and R&D Capabilities
The presentation showcased the combined entity's manufacturing network of 10 facilities with global approvals across Andhra Pradesh and Maharashtra. The company's "One R&D" initiative features a 200+ member team including 20+ PhDs, with 20 fully equipped analytical laboratories and dedicated capabilities for handling cytotoxic and complex molecules.
Source: Viyash Scientific Limited investor presentation for Q3FY26
Historical Stock Returns for Viyash Scientific
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.11% | +1.31% | +9.89% | +23.79% | +38.09% | -9.16% |
19
